Credit Suisse Downgrades Pfizer (PFE)

By Shauna O'Brien
February 7th, 2013

Try Dividend.com Premium for FREE »

Credit Suisse reported on Thursday that they have lowered their rating on biopharmaceutical company, Pfizer Inc.(PFE).

The firm has downgraded PFE from “Outperform” to “Neutral,” and has given the company a $29 price target. This price target suggests a 6% increase from the stock’s current price of $27.20.

Pfizer shares were down 19 cents, or -0.70% during Thursday morning trading. The stock has increased 29% in the past year.

The Bottom Line
Shares of Pfizer Inc.(PFE) have a 3.53% yield, based on Thursday morning’s price of $27.20.

Pfizer Inc.(PFE) is a “Recommended” dividend stock at this time, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

FREE Dividend Stock Newsletter

Get the Dividend.com email newsletter to receive:

A free copy of our acclaimed report, 5 Rules of Winning Dividend Stock Investing
Free daily investing tips and picks from Dividend.com CEO Paul Rubillo
Tons of great market analysis and recommendations

No Thanks

Free Dividend Newsletter

Get free dividend tips, analysis and updates straight to your inbox

MOST POPULAR ARTICLES ON DIVIDEND.COM

COMMENTS ON THIS ARTICLE

Comments are closed.

ABOUT THIS ARTICLE

You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Disclaimer: Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. The author is not registered as an investment adviser. The author may or may not hold positions in the securities mentioned in this article or video. The author relies upon the "publisher's exclusion" from the definition of "investment adviser" as provided under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws.

The Dividend Daily